C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.

ABSTRACT:

Background

Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease activity. Emerging treatments such as complement factor C5 inhibition (C5IT) and neonatal Fc receptor (FcRn) antagonism hold promise for these patients. However, the current landscape is hindered by a paucity of comparative data that is crucial for treatment decisions.

Objective

This study aims to compare the effectiveness and safety of C5IT and FcRn antagonists in a real-world setting.

Methods

A retrospective analysis of 153 MG patients from 8 German specialised MG centres receiving either C5IT (26 eculizumab, 80 ravulizumab) o

SUBMITTER: Huntemann N 

PROVIDER: S-EPMC12015038 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature